Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 1/2018

20.02.2018 | Letter to the Editor

PFO closure for secondary stroke prevention: is the discussion closed?

verfasst von: Joseph J. Shatzel, Molly M. Daughety, Vinay Prasad, Thomas G. DeLoughery

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Three previous reports of PFO closure for secondary stroke prevention failed to find any significant benefit. Recently however, three conflicting reports were published suggesting a benefit in select patients. Although we are enthusiastic for PFO closure in appropriate patients, caution is warranted in the extrapolation of this data and the application of this intervention to broader patient groups. Only small minorities of stroke patients are likely to benefit from PFO closure, the intervention has a notable complication rate, and it has not been compared against modern anticoagulation options. Clinicians should consider all of these points as discussions around PFO closure are likely to become more and more common going forward.
Literatur
1.
Zurück zum Zitat Mas JL, Derumeaux G, Guillon B et al (2017) Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 377:1011–1021CrossRefPubMed Mas JL, Derumeaux G, Guillon B et al (2017) Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 377:1011–1021CrossRefPubMed
2.
Zurück zum Zitat Saver JL, Carroll JD, Thaler DE et al (2017) Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 377:1022–1032CrossRefPubMed Saver JL, Carroll JD, Thaler DE et al (2017) Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 377:1022–1032CrossRefPubMed
3.
Zurück zum Zitat Sondergaard L, Kasner SE, Rhodes JF et al (2017) Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 377:1033–1042CrossRefPubMed Sondergaard L, Kasner SE, Rhodes JF et al (2017) Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 377:1033–1042CrossRefPubMed
4.
Zurück zum Zitat Furlan AJ, Reisman M, Massaro J et al (2012) Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 366:991–999CrossRefPubMed Furlan AJ, Reisman M, Massaro J et al (2012) Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 366:991–999CrossRefPubMed
5.
Zurück zum Zitat Carroll JD, Saver JL, Thaler DE et al (2013) Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 368:1092–1100CrossRefPubMed Carroll JD, Saver JL, Thaler DE et al (2013) Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 368:1092–1100CrossRefPubMed
6.
Zurück zum Zitat Meier B, Kalesan B, Mattle HP et al (2013) Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 368:1083–1091CrossRefPubMed Meier B, Kalesan B, Mattle HP et al (2013) Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 368:1083–1091CrossRefPubMed
7.
Zurück zum Zitat Meier B, Nietlispach F (2017) Editorial commentary: Closure of the patent foramen ovale viewed from a different angle. Trends Cardiovasc Med 27:582–584CrossRefPubMed Meier B, Nietlispach F (2017) Editorial commentary: Closure of the patent foramen ovale viewed from a different angle. Trends Cardiovasc Med 27:582–584CrossRefPubMed
9.
Zurück zum Zitat Hagen PT, Scholz DG, Edwards WD (1984) Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 59:17–20CrossRefPubMed Hagen PT, Scholz DG, Edwards WD (1984) Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 59:17–20CrossRefPubMed
10.
Zurück zum Zitat Connolly SJ, Eikelboom J, Joyner C et al (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806–817CrossRefPubMed Connolly SJ, Eikelboom J, Joyner C et al (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806–817CrossRefPubMed
11.
Zurück zum Zitat Bien JY, Daughety MM, Tao DL et al (2017) The safety of aspirin vs. direct oral anticoagulants: a meta-analysis of currently published clinical trials. Blood 130:3720 Bien JY, Daughety MM, Tao DL et al (2017) The safety of aspirin vs. direct oral anticoagulants: a meta-analysis of currently published clinical trials. Blood 130:3720
13.
Zurück zum Zitat Li L, Yiin GS, Geraghty OC et al (2015) Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. Lancet Neurol 14:903–913CrossRefPubMedPubMedCentral Li L, Yiin GS, Geraghty OC et al (2015) Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. Lancet Neurol 14:903–913CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Chai-Adisaksopha C, Crowther M, Isayama T et al (2014) The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 124:2450–2458CrossRefPubMed Chai-Adisaksopha C, Crowther M, Isayama T et al (2014) The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 124:2450–2458CrossRefPubMed
Metadaten
Titel
PFO closure for secondary stroke prevention: is the discussion closed?
verfasst von
Joseph J. Shatzel
Molly M. Daughety
Vinay Prasad
Thomas G. DeLoughery
Publikationsdatum
20.02.2018
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 1/2018
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-018-1633-2

Weitere Artikel der Ausgabe 1/2018

Journal of Thrombosis and Thrombolysis 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.